BridgeBio Oncology Therapeutics, Inc.
BBOT
$9.05
$0.171.91%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -62.25% | 432.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.74% | 63.43% | |||
| Operating Income | 11.74% | -63.43% | |||
| Income Before Tax | 13.32% | -57.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.32% | -57.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.32% | -57.40% | |||
| EBIT | 11.74% | -63.43% | |||
| EBITDA | 11.78% | -63.56% | |||
| EPS Basic | 52.87% | 97.96% | |||
| Normalized Basic EPS | 52.88% | 97.96% | |||
| EPS Diluted | 52.87% | 97.96% | |||
| Normalized Diluted EPS | 52.88% | 97.96% | |||
| Average Basic Shares Outstanding | 83.92% | 7,602.99% | |||
| Average Diluted Shares Outstanding | 83.92% | 7,602.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||